StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to “Hold”

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a report issued on Friday.

Other equities research analysts also recently issued research reports about the company. JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Chardan Capital reiterated a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, November 13th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Stock Up 7.4 %

Shares of MCRB opened at $0.91 on Friday. Seres Therapeutics has a 12-month low of $0.54 and a 12-month high of $2.05. The firm has a market capitalization of $154.59 million, a PE ratio of -3.94 and a beta of 2.13. The stock’s fifty day simple moving average is $0.82 and its 200-day simple moving average is $0.90.

Institutional Investors Weigh In On Seres Therapeutics

Several large investors have recently modified their holdings of MCRB. Vontobel Holding Ltd. bought a new stake in shares of Seres Therapeutics in the third quarter worth about $374,000. Geode Capital Management LLC increased its holdings in shares of Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after acquiring an additional 255,014 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Seres Therapeutics by 42.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after acquiring an additional 222,771 shares in the last quarter. FMR LLC increased its holdings in shares of Seres Therapeutics by 0.6% in the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after acquiring an additional 140,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Seres Therapeutics during the second quarter worth about $92,000. 59.34% of the stock is currently owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.